Login to Your Account

Start of Trial Triggers €4.3M Payment to Biocompatibles

By Nuala Moran

Wednesday, December 9, 2009

No Abstract


BioWorld International Correspondent

LONDON - Biocompatibles International plc moved onto the next stage of its collaboration with AstraZeneca plc, agreeing to a schedule for the Phase I and Phase II trials of the Type II diabetes drug CM3, and thus triggering a further €4.3 million (US$6.4 million) payment from the pharma company.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription